Acoustic Properties of Axial and Centrifugal Flow Left Ventricular Assist Devices and Prediction of Pump Thrombosis.


Journal

Mayo Clinic proceedings
ISSN: 1942-5546
Titre abrégé: Mayo Clin Proc
Pays: England
ID NLM: 0405543

Informations de publication

Date de publication:
04 2021
Historique:
received: 16 04 2020
revised: 11 09 2020
accepted: 06 10 2020
entrez: 5 4 2021
pubmed: 6 4 2021
medline: 27 4 2021
Statut: ppublish

Résumé

To characterize the properties of the audible tones produced by current left ventricular assist device (LVAD) pumps approved for use, and to ascertain if changes in those may be present in the setting of pump thrombosis. From August 31, 2016, to January 16, 2020, LVAD recipients consented to have surface recordings obtained using a high-fidelity digital stethoscope. Audio data were analyzed using digital recording and editing software to produce an acoustic spectrogram by Fast Fourier transformation. Recordings were obtained in 53 patient encounters (27 HeartMate II, 19 HeartWare and 7 HeartMate 3). In 12 patients (9 HeartMate II, 3 HeartWare) there was a clinical concern for pump thrombosis. In all patients and pump models, a fundamental frequency was noted, and the second and third harmonics were also clearly detectable. Where thrombosis occurred in the HeartMate II pump, the absolute (normal -46.9 [-57.5,-42.9] dB vs thrombosis -41.4 [-49.8,-26.8] dB; P=.08) and relative (normal 0.72 [0.62, 0.92] vs thrombosis 0.95 [0.86, 1.24]; P=.01) third harmonic frequencies were increased in amplitude. Where paired data were available, an increase in the absolute and relative third harmonic frequencies was observed in all patients. In the case of the HeartWare device, a consistent difference in harmonic amplitudes in the setting of thrombosis could not be identified. A consistent pattern of fundamental and harmonic frequencies is common to all LVADs currently approved for use. Alterations in the amplitude of higher order harmonics may signal the onset of pump thrombosis in axial flow LVADs.

Identifiants

pubmed: 33814091
pii: S0025-6196(20)31377-X
doi: 10.1016/j.mayocp.2020.10.043
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

887-900

Commentaires et corrections

Type : CommentIn

Informations de copyright

Copyright © 2020 Mayo Foundation for Medical Education and Research. Published by Elsevier Inc. All rights reserved.

Auteurs

Barry A Boilson (BA)

Department of Cardiovascular Diseases, Mayo Clinic, Rochester, MN. Electronic address: boilson.barry@mayo.edu.

Elizabeth L Bechtum (EL)

Department of Cardiac Surgery, Mayo Clinic, Rochester, MN.

Amy L Behnken (AL)

Department of Cardiac Surgery, Mayo Clinic, Rochester, MN.

Laura A Loga (LA)

Department of Cardiac Surgery, Mayo Clinic, Rochester, MN.

Angela J Luckhardt (AJ)

Department of Cardiac Surgery, Mayo Clinic, Rochester, MN.

Sarah D Schettle (SD)

Department of Cardiac Surgery, Mayo Clinic, Rochester, MN.

Alfredo L Clavell (AL)

Department of Cardiovascular Diseases, Mayo Clinic, Rochester, MN.

Dan Dragomir-Daescu (D)

Department of Physiology and Biomedical Engineering, Mayo Clinic, Rochester, MN.

John M Stulak (JM)

Department of Cardiac Surgery, Mayo Clinic, Rochester, MN.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH